It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2013
  5. Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin

March 25, 2013

Otsuka Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.

Pharmaceuticals

Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes;
Transferred Rights to Kyowa Hakko Kirin

Tokyo, Japan, March 29, 2013--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Kyowa Hakko Kirin Co., Ltd.(Kyowa Hakko Kirin) today announced that Otsuka has obtained marketing approval for Onglyza® Tablets 2.5mg and 5mg(generic name: saxagliptin hydrate) to treat type 2 diabetes. Otsuka signed an agreement with Kyowa Hakko Kirin in June 2012, transferring to Kyowa Hakko Kirin the exclusive development and marketing rights for Onglyza® in Japan.
Onglyza® was originated by Bristol-Myers Squibb. This oral hypoglycemic agent for diabetes acts by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down glucagon-like peptide-1 (GLP-1*1) and gastric inhibitory peptide (GIP). Once-daily dosing with Onglyza® produces a blood glucose-dependent reduction in blood sugar levels.
The efficacy and safety of Onglyza® were confirmed in accordance with the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents (PFSB/ELD Notification No. 0709-1, July 9, 2010).
Onglyza® has been approved in 85 countries, including the US and EU (as of February 2013).

Otsuka Pharmaceutical is to transfer marketing rights in Japan for Onglyza® to Kyowa Hakko Kirin, based on the 2012 agreement signed by the two companies. Otsuka will receive ¥8.2 billion from Kyowa Hakko Kirin upon approval, in addition to the initial payment of ¥3.0 billion. Moreover, Otsuka will receive running royalties after the launch of the drug in proportion to its revenue.
The approval of Onglyza® provides a new option in the treatment of type 2 diabetes and is therefore expected to help healthcare professionals and patients to manage type 2 diabetes.

  • *1:GLP-1 is secreted soon after eating, stimulating the pancreatic beta-cells and increasing insulin secretion. When DPP-4 is inhibited, blood levels of GLP-1 are maintained and rising blood sugar levels can be curbed.

Onglyza® product overview


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases